Table 1.

Baseline characteristics for the 20 subjects

	Age, years	Sex	BMI	Pack years	FEV1 (l)	FEV1 (% pred)	FEV1/FVC	Reversibility (ml) (<200 ml)	Regular β2-agonists
1	72	M	37	42	0.75	25	44	50	F, Sb
2	75	F	35	60	1.05	58	62	0	Sb
3	54	F	28	26	1.4	51	54	160	Sm, Sb
4	59	M	26	60	1.64	48	52	60	Sm, Sb
5	75	F	23	41	0.88	49	53	150	Sb
6	67	M	20	10	0.5	18	28	20	Sb
7	71	M	21	69	0.74	30	44	60	Sb
8	62	F	20	40	1.22	53	53	0	F, Sb
9	77	M	56	27	0.82	31	32	160	Sm, Sb
10	71	M	33	0	0.95	51	51	150	Sb
11	66	M	21	25	1.4	44	49	0	Sm, Sb
12	64	M	28	48	1.95	56	65	0	F,T
13	63	F	19	60	0.95	41	44	70	Sm, Sb
14	60	M	22	45	2.65	69	63	140
15	62	F	34	30	1.37	59	58	100	Sm,Sb
16	60	M	21	56	0.75	23	25	50	F, Sb
17	77	M	28	0	1.4	55	50	120	Sm, T
18	75	M	22	50	1.28	42	49	80	Sm
19	52	M	29	24	2.52	68	53	0	T
20	67	M	28	75	2.11	63	54	0	Sm

F, Formoterol; Sb, Salbutamol; Sm, Salmeterol; T, Terbutaline; BMI, body mass index, FEV₁, forced expiratory volume in 1 s.